1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Peripheral T-Cell Lymphomas (PTCL)-Pipeline Insights, 2016

Peripheral T-Cell Lymphomas (PTCL)-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Peripheral T-Cell Lymphomas (PTCL)-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Peripheral T-Cell Lymphomas (PTCL). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Peripheral T-Cell Lymphomas (PTCL). DelveInsight’s Report also assesses the Peripheral T-Cell Lymphomas (PTCL) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Peripheral T-Cell Lymphomas (PTCL)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Peripheral T-Cell Lymphomas (PTCL)-Pipeline Insights, 2016

Illustrative Table of contents

- Peripheral T-Cell Lymphomas (PTCL) Overview
- Peripheral T-Cell Lymphomas (PTCL) Pipeline Therapeutics
- Peripheral T-Cell Lymphomas (PTCL) Therapeutics under Development by Companies
- Peripheral T-Cell Lymphomas (PTCL) Filed and Phase III Products
- Comparative Analysis
- Peripheral T-Cell Lymphomas (PTCL) Phase II Products
- Comparative Analysis
- Peripheral T-Cell Lymphomas (PTCL) Phase I and IND Filed Products
- Comparative Analysis
- Peripheral T-Cell Lymphomas (PTCL) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products
- Peripheral T-Cell Lymphomas (PTCL) - Dormant Products
- Companies Involved in Therapeutics Development for Peripheral T-Cell Lymphomas (PTCL)
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Monotherapy Products
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Combination Products
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Route of Administration
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Route of Administration
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Molecule Type
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Molecule Type
- Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Discontinued Products
- Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Monotherapy Products
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Combination Products
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Route of Administration
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Route of Administration
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Molecule Type
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market  Forecast-2023

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in Russia

  • November 2016
    8 pages
  • Leukemia  

    Cancer  

    Radiography  

  • Russian Federat...  

View report >

Colorectal Cancer Statistics in the US - Forecast

  • November 2016
    14 pages
  • Colorectal Canc...  

  • United States  

View report >

Nursing Home Industry in Canada

  • November 2016
    13 pages
  • Nursing Home  

    Cancer  

  • Canada  

View report >

Related Market Segments :

Lymphoma

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.